Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design.
作者信息
Daniel-Fischer Lisa, Antlanger Marlies, Cejka Daniel, Eller Kathrin, Gauckler Philipp, Odler Balazs, Rudnicki Michael, Säemann Marcus D, Schmidt Alice, Sunder-Plassmann Gere, Wiesholzer Martin, Windpessl Martin, Zitt Emanuel, Koenig Franz, Greenbaum Larry A, Kronbichler Andreas, Aufricht Christoph
机构信息
Division of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.
Department of Internal Medicine 2, Faculty of Medicine, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
出版信息
Kidney Int Rep. 2023 Nov 3;9(2):478-481. doi: 10.1016/j.ekir.2023.10.027. eCollection 2024 Feb.
Abstract
摘要
相似文献
1
Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design.
Kidney Int Rep. 2023 Nov 3;9(2):478-481. doi: 10.1016/j.ekir.2023.10.027. eCollection 2024 Feb.
2
Computational drug repositioning of clopidogrel as a novel therapeutic option for focal segmental glomerulosclerosis.
Transl Res. 2023 Sep;259:28-34. doi: 10.1016/j.trsl.2023.04.001. Epub 2023 Apr 12.
3
Plasma microRNA-186 and proteinuria in focal segmental glomerulosclerosis.
Am J Kidney Dis. 2015 Feb;65(2):223-32. doi: 10.1053/j.ajkd.2014.07.013. Epub 2014 Sep 11.
4
Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis.
Biomed Res Int. 2016;2016:1630365. doi: 10.1155/2016/1630365. Epub 2016 Mar 21.
5
Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis.
Kidney Int Rep. 2020 May 26;5(8):1228-1239. doi: 10.1016/j.ekir.2020.05.024. eCollection 2020 Aug.
6
High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
Am J Nephrol. 2017;46(2):108-113. doi: 10.1159/000477944. Epub 2017 Jul 13.
7
A case of recurrent focal segmental glomerulosclerosis (FSGS) involving massive proteinuria (>50 g/day) immediately after renal transplantation.
Clin Transplant. 2011 Jul;25 Suppl 23:53-8. doi: 10.1111/j.1399-0012.2011.01455.x.
8
CUBN gene mutations may cause focal segmental glomerulosclerosis (FSGS) in children.
BMC Nephrol. 2022 Jan 3;23(1):15. doi: 10.1186/s12882-021-02654-x.
9
10
Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease.
Lancet. 1996 Jan 27;347(8996):231-3. doi: 10.1016/s0140-6736(96)90406-7.
引用本文的文献
1
Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches.
Proteomics. 2025 Jun;25(11-12):e202400109. doi: 10.1002/pmic.202400109. Epub 2025 Jan 31.
2
Drug repurposing for glomerular diseases: an underutilized resource.
Nat Rev Nephrol. 2024 Nov;20(11):707-721. doi: 10.1038/s41581-024-00864-8. Epub 2024 Jul 31.
本文引用的文献
1
Computational drug repositioning of clopidogrel as a novel therapeutic option for focal segmental glomerulosclerosis.
Transl Res. 2023 Sep;259:28-34. doi: 10.1016/j.trsl.2023.04.001. Epub 2023 Apr 12.
2
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.
Mol Ther. 2022 Sep 7;30(9):3017-3033. doi: 10.1016/j.ymthe.2022.06.019. Epub 2022 Jul 5.
3
Interventions for focal segmental glomerulosclerosis in adults.
Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3.
4
Antiplatelet agents for chronic kidney disease.
Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.
5
Informing single-arm clinical trials with external controls.
Nat Rev Drug Discov. 2020 Dec;19(12):821-822. doi: 10.1038/d41573-020-00146-5.
6
A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis.
PLoS One. 2019 Mar 28;14(3):e0214332. doi: 10.1371/journal.pone.0214332. eCollection 2019.
7
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091.
8
"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?
Clin Pharmacol Ther. 2016 Dec;100(6):699-712. doi: 10.1002/cpt.515. Epub 2016 Oct 19.
Zotero 插件